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Abstract
Pilocytic astrocytomas represent the most common glioma subtype in young patients and account for 5.4% of all gliomas.
They are characterized by alterations in the RAS–MAP kinase pathway, the most frequent being a tandem duplication on
chromosome 7q34 involving the BRAF gene, resulting in oncogenic BRAF fusion proteins. BRAF fusion involving the
KIAA1549 gene is a hallmark of pilocytic astrocytoma, but it has also been recorded in rare cases of gangliogliomas, 1p/19q
co-deleted oligodendroglial tumors, and it is also a common feature of disseminated oligodendroglial-like leptomeningeal
neoplasm. In some difficult cases, evidence for KIAA1549-BRAF fusion is of utmost importance for the diagnosis. Moreover,
because the KIAA1549-BRAF fusion constitutively activates the MAP kinase pathway, it represents a target for drugs such as
MEK inhibitors, and therefore, the detection of this genetic abnormality is highly relevant in the context of clinical trials
applying such new approaches. In the present study, we aimed to use the high sensitivity of Droplet Digital PCR
(DDPCR™) to predict KIAA1549-BRAF fusion on very small amounts of formalin-fixed paraffin-embedded tissue in routine
practice. Therefore, we analyzed a training cohort of 55 pilocytic astrocytomas in which the KIAA1549-BRAF fusion status
was known by RNA sequencing used as our gold standard technique. Then, we analyzed a prospective cohort of 40 pilocytic
astrocytomas, 27 neuroepithelial tumors remaining difficult to classify (pilocytic astrocytoma versus ganglioglioma or
diffuse glioma), 15 dysembryoplastic neuroepithelial tumors, and 18 gangliogliomas. We could demonstrate the usefulness
and high accuracy (100% sensitivity and specificity when compared to RNA sequencing) of DDPCR™ to assess the
KIAA1549-BRAF fusion from very low amounts of DNA isolated from formalin-fixed paraffin-embedded specimens. BRAF
duplication is both necessary and sufficient to predict this fusion in most cases and we propose that this single analysis could
be used in routine practice to save time, money, and precious tissue.
Introduction
Pilocytic astrocytomas account for 5.4% of all gliomas [1].
They represent the most common glioma subtype in young
patients and mainly occur within the cerebellum, although
other common locations are optic nerve, optic chiasm/hypo-
thalamus, thalamus and basal ganglia, brain stem, and cerebral
hemispheres. According to the 2016 WHO classification of
central nervous system tumors, they are now classified among
the group of “other astrocytic tumors” in order to emphasize
that they are circumscribed in contrast to other diffuse astro-
cytic and oligodendroglial tumors [2, 3]. Pilocytic astro-
cytomas are characterized by alterations in the RAS–MAP
kinase pathway, the most frequent being a tandem duplication
on chromosome 7q34 involving the BRAF gene, resulting in
oncogenic BRAF fusion proteins [4]. The most common
partner is the KIAA1549 gene. In this case, a fragment of
approximately 2Mb involving parts of both genes is
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duplicated and inserted at the breakpoint such that the 5′-end
of the KIAA1549 gene becomes fused with the 3′-end of the
BRAF gene (Fig. 1). To date, nine different combinations of
KIAA1549 and BRAF gene fusion have been described in the
literature. The most common is a fusion between exon 16 of
KIAA1549 and exon 9 of BRAF (KIAA1549-BRAF 16;9
fusion, 78%). Less frequent variants include fusion between
KIAA1549 exon 15 and BRAF exon 9 (KIAA1549-BRAF 15;9
fusion, 13%) and KIAA1549 exon 16 and BRAF exon 11
(KIAA1549-BRAF 16;11 fusion, 7%) [5].
Because the gene fusions involve different combinations of
KIAA1549 and BRAF exons, it remains difficult to identify
them by RT-PCR especially from formalin-fixed paraffin-
embedded tissues. Moreover, because in some cases material
remains scarce, technical failure is common. Recently, a study
has reported the usefulness of NanoString nCounter system to
detect KIAA1549-BRAF fusion from RNA extracted from
formalin-fixed paraffin-embedded tissue but the amount of
material needed remains high [6]. FISH analysis is widely
used by some centers: it is sensitive to detect BRAF dupli-
cation but it may be difficult to interpret, especially in cases
showing aneuploidy. FISH may also allow detecting the
KIAA1549-BRAF fusion by using appropriate probes but here
again the interpretation requires an experimented pathologist
or cytogeneticist and it remains difficult in some cases.
However, in some instances, evidence for KIAA1549-BRAF
fusion is of utmost importance for the diagnosis.
In addition to KIAA1549-BRAF fusion status, other
genetic alterations might be of interest to be searched for in
DNA extracted from low-grade gliomas such as FGFR1 or
BRAF point mutation or FGFR1 duplication as examples.
Therefore, a technique that would allow KIAA1549-BRAF
fusion detection on DNA extracted from small amount of
formalin-fixed paraffin-embedded samples would be of
substantial value in routine practice. DDPCR™ represents a
powerful single-molecule counting strategy to detect minute
amounts of genetic material with performance surpassing
many quantitative methods. It allows the measuring of low
amplitude Copy Number Variation and the accurate
counting of alleles from DNA isolated from a mixture of
heterogeneous cell populations and from highly degraded
DNA prepared from formalin-fixed paraffin-embedded tis-
sue samples [7]. This technique was successfully used in
our department for the detection of several molecular
alterations in different diseases including the detection of
the internal tandem duplication of the tyrosine-kinase
domain of FGFR1 gene in dysembryoplastic neuroepithe-
lial tumors [8]. In the present study, we wanted to utilize the
sensitivity of DDPCR™ to show the occurrence of gene
duplications on very small amounts of formalin-fixed par-
affin-embedded tissue in routine practice. Because the
KIAA1549-BRAF gene fusion is the consequence of a tan-
dem duplication involving parts of both genes, we
hypothesized that the identification of duplicated regions in
these two genes was directly correlated to the detection of
fusion transcripts. Moreover, the duplication of KIAA1549
exon 16 suggest the occurrence of a KIAA1549-BRAF
fusion transcript involving exon 16 (Fig. 1).
To test this hypothesis, we first used a training cohort of
55 pilocytic astrocytomas in which the KIAA1549-BRAF
fusion status was known (RNA sequencing on frozen spe-
cimen). In this cohort of patients we performed DDPCR™
from DNA samples extracted from formalin-fixed paraffin-
embedded tissues. The sensitivity and specificity of this
method for each designed assay were compared against
gold standard RNA-sequencing analysis. In addition, we
analyzed the KIAA15149-BRAF fusion status in a pro-
spective cohort of 40 pilocytic astrocytomas, 27 low-grade
neuroepithelial tumors remaining difficult to classify (pilo-
cytic astrocytoma versus ganglioglioma and pilocytic
astrocytoma versus diffuse glioma), 15 dysembryoplastic
neuroepithelial tumors, and 18 gangliogliomas.
Materials and methods
Patients
Training cohort
The first series involved formalin-fixed paraffin-embedded
DNA samples from 31 pilocytic astrocytomas with available
KIAA1549-BRAF fusion status (RNA-sequencing analysis
on frozen specimen) provided by the German Cancer
Research Center in Heidelberg. Among them, 16 cases were
KIAA1549-BRAF fused and 15 were not fused. Regarding
these 15 cases, 2 of them displayed trisomy 7. The second
series, also provided by the German Cancer Research Center
included formalin-fixed paraffin-embedded scrolls from 19
pilocytic astrocytoma samples, all displaying KIAA1549-
BRAF fusion status demonstrated by RNAseq (RNA-
sequencing analysis performed on frozen specimen).
We also analyzed DNA from five additional gliomas
demonstrating partial chromosome 7q gain. Therefore, the
training cohort comprised a total of 55 cases: 20 not-fused
cases (2 trisomy 7 and 5 7q gain), 9 KIAA1549-BRAF 15;9
fusion cases, 26 cases involving KIAA1549 exon 16 fusion
(3 with 16;11 fusion and 23 with 16;9 fusion).
Prospective cohort
The second cohort comprised samples from 100 French
patients diagnosed as pilocytic astrocytomas (40 cases),
gangliogliomas (18 cases), dysembryoplastic neuroepithelial
tumors (15 cases), and 27 neuroepithelial tumors that
remained difficult to classify (gangliogliomas versus pilocytic
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astrocytoma, 6 cases and diffuse glioma versus pilocytic
astrocytoma, 21 cases). Some examples of cases difficult to
classify are shown in Fig. 2. One case (Fig. 2a–c) corresponds
to a well-circumscribed tumor located in the cerebellar
hemisphere (Fig. 2a). Pathological features show a prolifera-
tion of elongated bipolar glial cells associated with numerous
Rosenthal fibers (Fig. 2b). Although these pathological fea-
tures are in keeping with a pilocytic astrocytoma, the high
expression of neurofilament is unusual (Fig. 2c) and a dif-
ferential diagnosis with a ganglioglioma was considered.
Another case (Fig. 2d–f) concerns a temporal cystic lesion
with a mural nodule enhanced after gadolinium injection.
(Fig. 2d). Microscopic examination demonstrates a pro-
liferation of elongated cells associated with Rosenthal fibers
and eosinophilic granular bodies (Fig. 2e). Perivascular lym-
phocytes accumulation, as usually observed in gang-
liogliomas, was seen but no neuronal component (Fig. 2f).
This observation might correspond to the glial component of a
ganglioglioma but the diagnosis of pilocytic astrocytoma
cannot be ruled out. The last example (Fig. 2g–i) corresponds
to a tumor of the medulla (Fig. 2g). A biopsy was performed.
Pathological examination of the tiny samples demonstrates a
proliferation of monomorphous cells within a myxoid back-
ground (Fig. 2h). Because of lack of Rosenthal fibers, pre-
sence of axons, numerous mitotic figures, and high
proliferation index (Fig. 2i) a differential diagnosis with an
infiltrating glioma was considered.
Methods
Genomic DNA extraction
Areas of viable and representative tumor following review
of all blocks of the prospective cohort were marked by a
pathologist (DFB). In all cases the percentage of tumor cells
was above 60%. Then, tumor DNA was extracted from 4×5
µm thick sections of formalin-fixed paraffin-embedded tis-
sue samples after dewaxing, as previously described [9].
The diameter of the formalin-fixed paraffin-embedded sec-
tions varied from 5 mm to 2 cm.
RNA sequencing
RNA sequencing was performed on frozen tissue in Hei-
delberg (German Cancer Research Center) as previously
described [10].
KIAA1549-BRAF fusion status
In order to search for a duplication of the KIAA1549 and
BRAF genes that would be associated with the KIAA1549-
BRAF fusion we developed droplet digital PCR (DDPCR™,
Bio-rad) assays to screen copy number variation duplica-
tions. Therefore, we designed our assay to quantify DNA
copy number of KIAA1549 (exons 4, 14, 15, and 16) and
BRAF (exon 14) and compared the results respectively with
DNA copy number of KIAA1549 (exon 20) and BRAF
(exon 3) that are described to be not affected by the
duplication (Fig. 1) [11]. Moreover, because the duplica-
tion, if it exists, also affects the Ubinuclein 2 (UBN2) gene
but not the Transmembrane protein 213 (TMEM213) gene
(Fig. 1), we also designed probes targeting UBN2 exon 17
and TMEM213 intron 2 and we compared DNA copy
number of UBN2 exon 17 with DNA copy number of
TMEM213 intron 2 in order to confirm the duplication. As
previously reported [8], we theoretically considered a
sample as duplicated if the mean copy number variation
value of the ratio between the two exons analyzed was
above 2.25 and the copy number variation min above 2.00
(CI 95%, Poisson law), with a minimum DNA
Fig. 1 Schematic representation of the normal portion of chromosome
7q34 including KIAA1549, UBN2, and BRAF genes and the gene
fusion event including some exons of BRAF and KIAA1549 genes.
UBN2 gene has been described to be affected by this duplication
whereas TMEM213 gene is not
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concentration of 100 copies/μL of DNA (330 pg/μL) ana-
lyzed with 35.000 nano-droplets of DDPCR™.
DDPCR™ analysis was performed as previously
described [8]. Briefly, each 21-µl reaction mixture contained
5 µL of DNA template, 2 × DDPCR™ supermix for probes
(no dUTP) and BRAF exon 14 (FAM™) and exon 3
(HEX™) assays, or KIAA1549 exon 4 (FAM™) and exon
20 (HEX™), or KIAA1549 exon 14 (FAM™) and exon 20
(HEX™), or KIAA1549 exon 15 (FAM™) and exon 20
(HEX™), or KIAA1549 exon 16 (FAM™) and exon 20
(HEX™), or UBN2 exon 17 (FAM™) and TMEM213
intron 2 (HEX™). The assays were purchased as a 20×
premix of primers and probes and used at 1× concentration
(Bio-Rad Laboratories). The 1× concentration of this assay
comprised 900 nM forward primer, 900 nM reverse primer,
and 250 nM probe. Experiments were performed in tripli-
cate for each sample. Primers, hydrolysis probe sequences
and DDPCR™ conditions are reported in Table 1.
Fig. 2 Example of three cases difficult to classify. Case 1: a T2
weighted magnetic resonance imaging (MRI) showing a well limited
tumor located in the cerebellum. b Hematoxylin and eosin (HE)
stained section demonstrating a proliferation of elongated bipolar glial
cells associated with numerous Rosenthal fibers (HE, ×40). c Presence
of numerous axons revealed by anti-neurofilament immunostaining
(×20). In this case, KIAA1549-BRAF fusion was recorded and final
diagnosis was pilocytic astrocytoma. Case 2: d Temporal cystic lesion
with a mural nodule enhanced after gadolinium injection on MRI. e
Proliferation of elongated cells associated with Rosenthal fibers and
eosinophilic granular bodies and perivascular lymphocytic infiltrate
(HE, ×40). f Neurofilament immunostaining reveals absence of neu-
ronal component (×20). This case exhibit neither KIAA1549-BRAF
fusion nor BRAFV600E mutation and final diagnosis remains elusive.
Case 3: g T2 weighted MRI showing a well-circumscribed spinal
tumor. h Proliferation of monomorphous bipolar cells within a myxoid
background (HE, ×40). i High proliferation index evaluated by anti-
Ki67 antibody (×40). KIAA1549-BRAF fusion was recorded and final
diagnosis was pilocytic astrocytoma
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Defining limits of BRAF exon 14/exon 3 duplication
detection
In order to determine the limits of detection of this
DDPCRTM assay, we empirically characterized the limits of
detection of BRAF exon 14/exon 3 duplication, by deter-
mining the amounts of DNA needed regarding different
copy number variation values. The copy number variation
represents for a haploid genome the ratio of target DNA to
reference DNA multiplied by two. To achieve our goal, we
made four mixtures from several pools of DNA from the
training cohort with known KIAA1549:BRAF duplication
status. One with a pool of samples displaying duplicated
DNA BRAF exon 14/exon 3 (ratio of target DNA to refer-
ence DNA= 1.385, copy number variation= 2.77). Note
that a duplicated sample with one additional allelic copy
would have a theoretical copy number variation of 3.0, so
this pool displaying a copy number variation of 2.77 cor-
responds in theory to a duplication in 77% of the cells and
likely reflects <100% tumor purity as well as possibly some
intra-tumoral heterogeneity of presence of the fusion. A
second pool of samples without BRAF exon 14/exon 3
duplication (ratio of target DNA to reference DNA= 0.98;
copy number variation= 1.96) was also generated. The last
two pools were obtained by mixing DNA from the first and
second DNA pools, displaying respectively copy number
variation values of 2.33 and 2.21 in order to frame the
cut-off value copy number variation= 2.25. Each mixture
was then diluted in cascade, to a theoretical minimum
detection value of 300 pg of total DNA per DDPCR™ assay
(Fig. 3).
Statistical analysis
The χ2 test (or Fisher’s exact test, as appropriate) was used
to correlate the following variables: histological diagnosis
and copy number variation results. The test was two-sided
and the statistical significance was defined as p < 0.05.
Analyses were conducted using PASW Statistics version
17.02 (IBM SPSS Inc., Chicago, IL, USA).
Table 1 Primers, hydrolysis probes sequences and DDPCR™ conditions for the detection of UBN2, TMEM213, BRAF, and KIAA1549 copy
number variations, reflecting duplication of these genes and at last, KIAA1549-BRAF fusion event
Primers and FAM probe sequences for
exon 17 UBN2 detection
Forward: 5′-GGAGCTCAGCATGCAGCAA -3′
Reverse: 5′-GATGAAGGAGGTGGCGTTCTC-3′
Probe: 5′-ACTCACCTCTGCCTGCACACTTACAGCAAG-3′
Primers and HEX probe sequences for
intron 2 TMEM213 detection
Forward: 5′-CAACAGCAAAGTGGAAGAAAGGAT-3′
Reverse: 5′-CTCCTGGTCATGTCCCAGTTC-3′
Probe: 5′-CCGCATTCTACAGGATCGGCCTTAGC-3′
Primers and HEX probe sequences for
exon 3 BRAF detection
Forward: 5′-CAAGTCACCACAAAAACCTATCGT-3′
Reverse: 5′-ATACAAAGAAACAGCAAAATGGTGAT-3′
Probe: 5′-AGAGTCTTCCTGCCCAACAAACAGAGGAC-3′
Primers and FAM probe sequences for
exon 14 BRAF detection
Forward: 5′-AAATGATGTTTTGTTTTTCAGTTACTT-3′
Reverse: 5′-GCAGACAAATTTCAGGAAGGA-3′
Probe: 5′-ACGCCAAGTCAATCATCCACAGAGA-3′
Primers and FAM probe sequences for
exon 4 KIAA1549 detection
Forward: 5′-TGTCCGTGACCAGACTCCTTT-3′
Reverse: 5′-TGTCTCACCTGTTTGAACTTGGAA-3′
Probe: 5′-CCTGTCTGTGAAACCTTCTTTCCTTGTGCC-3′
Primers and FAM probe sequences for
exon 14 KIAA1549 detection
Forward: 5′-CGGGACCTCTATGGCTGTCTT-3′
Reverse: 5′-GGTGCTCGATCTCAGACTTGTG-3′
Probe: 5′-TTCCTCAGATTCAGACCGCGCTGC-3′
Primers and FAM probe sequences for
exon 15 KIAA1549 detection
Forward: 5′-AAGCCTCGCCGGAAACA-3′
Reverse: 5′-CATCGCTGTCTGTGGTGATGA -3′
Probe: 5′-TCAACGGCTGTCCTGCCGACG-3′
Primers and FAM probe sequences for
exon 16 KIAA1549 detection
Forward: 5′-TCCTTTGCCATTTCTCATTGTAGTC-3′
Reverse: 5′-CTGGATACCTCCCCAGTTCCA-3′
Probe: 5′-CAGCCGATGTGCAGACACCATCCTC-3′
Primers and HEX probe sequences for
exon 20 KIAA1549 detection
Forward: 5′-GCACCGTGCAGAACTTCCA-3′
Reverse: 5′-GTTGATTTCCTTTTGGTCTTGCTT-3′
Probe: 5′-CAGATTTGCCAAGTATCCGCTTCCTGTG-3′
Thermocycler conditions 95 °C, 10 min (1 cycle)
94 °C, 30 s—55 °C, 1 min (40 cycles)
98 °C, 10 min (1 cycle)
15 °C ∞
Use of a heated lid set to 105 °C
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Results
In this study we aimed to set up a robust method to
search for KIAA1549-BRAF fusion status by DDPCR™
on formalin-fixed paraffin-embedded DNA samples. To
achieve this goal, we first analyzed BRAF duplication
status, UBN2 duplication status, KIAA1549 and
TMEM213 duplication status in the training cohort. We
used RNA sequencing as the gold standard method to
calculate the sensitivity and specificity of each
DDPCR™ assay and to define the best assay to detect
KIAA1549-BRAF fusion. We also searched for
KIAA1549-BRAF fusion status by DDPCR™ in the
prospective cohort.
1. Training cohort (55 cases) (Table 2)
BRAF gene duplication status
Copy number variation value of BRAF exon 14 over BRAF
exon 3 was calculated for all samples. All cases exhibiting
KIAA1549-BRAF fusion by RNAseq demonstrated BRAF
gene duplication (35/35). However, none of the non-fused
cases assessed by RNAseq displayed BRAF gene duplica-
tion (20/20). Importantly, none of the seven cases that
displayed chromosome 7 trisomy (two cases) or partial
chromosome 7q gain (five cases) displayed BRAF gene
duplication relative to the adjacent control locus.
Fig. 3 Empirical characterization of the DDPCRTM limits of detection
for BRAF exon 14/exon 3 duplication by determining the minimal
amounts of DNA needed regarding different copy number variation
values, in particular around the theoretical threshold value of copy
number variation= 2.5 (copy number variation min 2.0; CI:95%,
Poisson Law). The first copy number variation values (2.77) for the
duplicated DNA pool corresponds to a ratio of 1385 and means in
theory a monoallelic duplication in 77% of tumor cells. 33 and 21%
were obtained by mixing duplicated and normal DNA pool in order to
frame the cut-off value copy number variation= 2.25 corresponding to
a duplication in 25% of tumor cells; 0% corresponds to the normal
DNA pool. The gray gradient arrow corresponds to a dilution of each
mixed and normal DNA at 12.5 ng, 10.0 ng, 2.25 ng, 0.85 ng, and 0.3
ng total DNA in the assay (*=5 µL DNA). a copy number variation
values for each dilution of mixed and normal samples. b Concentra-
tions expressed in copies/µL of DDPCRTM (20 µL) for BRAF exon 14
(blue) and BRAF exon 3 (green) for each dilution of mixed and normal
samples, ** corresponds to the concentration of DNA expressed in ng/
μL of DNA samples. The limit of detection is shown schematically by
the gray vertical rectangle, it borders the value of 0.3 ng of total DNA
to which the values of copy number variation ≥ 2.25; copy number
variation min ≥ 2.0 (CI 95% Poisson law) are no longer respected
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Table 2 Results of the DDPCRTM assay performed on the training cohort
Grey cells correspond to unexpected results regarding RNA seq gold standard
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UBN2 gene duplication status
UNB2 gene duplication status was assessed by the ratio of
UBN2 over TMEM213. All cases exhibiting KIAA1549-
BRAF fusion by RNAseq demonstrated UBN2 gene dupli-
cation (35/35). Again, none of the seven cases with
numerical abnormalities of chromosome 7 displayed UBN2
gene duplication.
Sensitivity and specificity of BRAF exon 14 and UBN2
gene duplication status assessed by DDPCR™ as compared
to RNAseq as the gold standard to detect KIAA1549-BRAF
fusion were 100%.
KIAA1549 gene duplication status
To investigate the KIAA1549 duplication status, we used in
a first step three sets of primers, allowing us to calculate the
following copy number variation ratio: KIAA1549 exon 14/
KIAA1549 exon 20, KIAA1549 exon 15/KIAA1549 exon 20,
and KIAA1549 exon 16/KIAA1549 exon 20.
According to Fig. 1, we postulated that in all KIAA1549-
BRAF fused cases, duplication of KIAA1549 exon 14/
KIAA1549 exon 20 and KIAA1549 exon 15/KIAA1549 exon
20 should be present. Duplication of and KIAA1549 exon
16/KIAA1549 exon 20 might be observed only in fusion
cases showing a KIAA1549-BRAF transcript involving
exon 16.
1. Unexpectedly, duplication of KIAA1549 exon 14/
KIAA1549 exon 20 was only recorded in 24/35 cases
displaying fusion transcripts by RNAseq. Although
we have no clear explanation for this technical failure
it might be secondary to the primer set designed or to
a genomic instability in this peculiar genomic
sequence. Among the 15 cases displaying no fusion
by RNAseq, we recorded one case with the KIAA1549
exon 14/KIAA1549 exon 20 duplication. Of impor-
tance, this case did not show BRAF duplication. This
assay compared to the RNAseq results only showed a
sensitivity and a specificity of 68.6 and 93.3%,
respectively.
2. Duplication of KIAA1549 exon 16/KIAA1549 exon 20
was recorded in 23/35 cases. Interestingly all cases
showing KIAA1549-BRAF 15;9 fusion by RNAseq
did not have KIAA1549 exon 16/KIAA1549 exon 20
duplication (9/9). Surprisingly, among the 23 cases
that demonstrated KIAA1549-BRAF 16;9 fusion by
RNAseq, 3 cases did not show this duplication. This
assay compared to RNAseq results showed a
sensitivity and a specificity of 88.5 and 100%,
respectively.
3. Duplication of KIAA1549 exon 15/KIAA1549 exon 20
was recorded in 31/35 cases. One of the negative
cases demonstrated KIAA1549-BRAF 15;9 fusion by
RNAseq, and the three others a KIAA1549-BRAF 16;9
fusion. This assay compared to RNAseq results
showed a sensitivity and a specificity of 88.6 and
100%, respectively.
4. We hypothesized that the lack of sensitivity of these
three assays might be attributed to the variability of
the involved region since the targeted exons are
located near to the breakpoint junction. Because
KIAA1549 exon 4 is closer to UBN2 than exon 14 and
because in all cases described in the literature, exon 4
is always fused, we then decided to analyze and
calculate the KIAA1549 exon 4/KIAA1549 exon 20
copy number variation ratio. Only one case did not
show duplication but it demonstrated a mean copy
number variation value of the ratio of 2.23, very close
to the cut-off value of 2.25. All other cases (34/35)
exhibited this duplication, whereas the 15 cases
displaying no fusion by RNAseq did not (15/15).
This assay, compared to the RNAseq gold standard
reached a sensitivity of 97.1% with always a
specificity of 100%.
Definition of KIAA1549-BRAF fusion status according to
DDPCR™
In summary, for this cohort of 55 samples, none of the 20
non-fused cases showed BRAF exon 14 and KIAA1549
exon 4 duplication, and only one case was recorded with
KIAA1549 exon 14 duplication but normal exon 4 (although
the values for the latter were very close to the threshold for
scoring duplication). All RNAseq-fused cases (35) were
BRAF exon 14 duplicated and 34/35 were KIAA1549 exon 4
duplicated. Of note, this discrepant case (83010) was
KIAA1549 exon 14, 15, and 16 duplicated. Since all
KIAA1549-BRAF fused cases demonstrated BRAF (and
UBN2) duplication, we could state that if a sample did not
demonstrate BRAF duplication, KIAA1549-BRAF fusion did
not occur.
Defining limits of BRAF exon 14/exon 3 duplication
detection
In order to determine the limits of detection of this
DDPCRTM assay, we have empirically characterized the
minimal amounts of DNA needed to detect the BRAF exon
14/exon 3 duplication according to different copy number
variation values. The results showed that one nanogram of
amplifiable DNA is sufficient to detect the amplification if
this alteration is present in at least 25% of the total amounts
of analyzed cells (this corresponds to the cut-off copy
number variation value= 2.25). Although the standard error
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increases when the total amounts of DNA decrease it still
gives significant results with 1 ng of DNA (Fig. 3).
2. Prospective cohort (100 cases)
When we started to study the prospective cohort, we ana-
lyzed by DDPCR™ BRAF exon 14 over BRAF exon 3 and
KIAA1549 exon 14 over KIAA1549 exon 20.
Duplication data were not exploitable for five cases; this
represents a relatively low failure rate (5%) given the difficulties
commonly encountered with formalin-fixed paraffin-embedded
sample analysis. BRAF duplication was recorded in 20/40 pilo-
cytic astrocytomas (50%), 3/18 gangliogliomas (16.7%), 0/15
dysembryoplastic neuroepithelial tumors, and in 4/27 tumors
difficult to classify (Fig. 4): for one of them, case 1 (Fig. 2a–c),
the diagnosis could not be made between pilocytic astrocytoma
and ganglioglioma, and for the three other cases, although the
pathological features were compatible with a pilocytic astro-
cytoma, a diagnosis of infiltrating glioma could not be ruled out
as illustrated by case 3 (Fig. 2g–i). In some cases difficult to
classify (pilocytic astrocytoma versus ganglioglioma),
KIAA1549-BRAF fusion was not recorded and diagnosis remains
elusive (case 2, Fig. 2d–f). According to the results of the
training cohort, we could extrapolate that the 27 cases exhibiting
BRAF duplication displayed KIAA1549-BRAF fusion. In accor-
dance, 25/27 cases also displayed a KIAA1549 exon 14/
KIAA1549 exon 20 duplication. Importantly, the two negative
cases displayed a duplication of KIAA1549 exon 4/KIAA1549
exon 20. Therefore, in accordance with the literature, KIAA1549-
BRAF fusion detection was significantly linked to the pilocytic
astrocytoma diagnosis (p= 0.004). Of note, we observed a
KIAA1549 exon 14/KIAA1549 exon 20 duplication in 18 cases
that did not demonstrate BRAF duplication. It was not possible to
test KIAA1549 exon 4/KIAA1549 exon 20 duplication in these
cases because DNA as well as formalin-fixed paraffin-embedded
material were no longer available. The histological diagnoses of
these tumors were: six pilocytic astrocytomas, seven gang-
liogliomas, four dysembryoplastic neuroepithelial tumors, and
one unclassified glioma. According to the criteria defined above,
these cases would be considered as fusion negative.
Discussion
In this study, we report the usefulness of DDPCR™ to
predict KIAA1549-BRAF fusion from very low amounts of
DNA isolated from formalin-fixed paraffin-embedded spe-
cimens. In our reference cohort, this method displayed
100% sensitivity and specificity when compared to RNA
sequencing as a “gold standard”. Because DDPCR™ is
highly sensitive, we were able to assess the KIAA1549-
BRAF fusion in a sample with a minimum of 850 pg of total
DNA per DDPCR™ assay. We also showed that BRAF
duplication was both necessary and sufficient to predict
KIAA1549-BRAF fusion in most cases and we proposed that
this single analysis could be used in routine practice to save
time, money and precious tissue. In keeping with this result,
many centers accept the demonstration of a duplication at
7q34 encompassing the BRAF gene (usually by FISH) as
evidence of the KIAA1549-BRAF fusion. Importantly, other
less frequent fusions involving BRAF gene have been
reported in pilocytic astrocytomas such as FAM131-BRAF,
RNF130-BRAF, CLCN6-BRAF, MKRN1-BRAF, GNAI1-
BRAF, and more recently GTF2I-BRAF [10, 12–14].
GTF2I-BRAF and MKRN1-BRAF fusions on one hand, and
FAM131-BRAF fusion on the other hand are formed
respectively by tandem duplication and interstitial deletion
on chromosome arm 7q34 (involving BRAF). In these
extremely rare cases, DDPCR™ might show a BRAF
duplication or deletion without KIAA1549 duplication,
whereas the other fusions are the result of translocations or
inversions and thus are not associated with copy number
variation of the BRAF gene. KIAA1549-BRAF fusion is a
hallmark of pilocytic astrocytomas [4].
As shown in Table 3, the use of the DDPCR™ to
demonstrate the KIAA1549-BRAF fusion offers several
advantages over the various commonly used techniques. This
system is of interest in routine practice since results can be
obtained quickly and with a high success rate even on small
and damaged formalin-fixed paraffin-embedded samples. In
addition, it allows searching for other molecular anomalies of
interest from the extracted DNA. The sensitivity and speci-
ficity of the DDPCR™ is high in comparison with RNAseq,
nanostring, and CGH-array but it allows the evaluation of
only a limited number of genetic abnormalities. As compared
to the DDPCR™, FISH presents the main advantage of not
requiring any expensive equipment, but its performances are
mainly dependent on the operator.
Fig. 4 Correlation between KIAA1549-BRAF fusion detection by
DDPCR™ and tumor type in the prospective cohort (n= 100)
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Although not all pilocytic astrocytomas display the
KIAA1549-BRAF fusion, it is extremely common in the
cerebellum (up to 90% of cases for some authors [4]), but
less frequent in supratentorial locations. KIAA1549-BRAF
fusion has also been recorded in rare cases of gang-
liogliomas [15], 1p/19q co-deleted oligodendrogliomas
[16], and it is also a common feature of diffuse leptome-
ningeal glioneuronal tumors (DLGNT [17],). Interestingly
these three diagnoses represent differential diagnoses for
pilocytic astrocytoma. In fact, pathological diagnosis of
pilocytic astrocytoma is easy when it demonstrates typical
biphasic architecture and Rosenthal fibers but it might be
tricky in cases exhibiting monomorphous appearance of
cells closely resembling oligodendrocytes. When such a
pattern is obvious, differential diagnosis might be discussed
regarding the location of the tumors. When the tumor
demonstrates a typical leptomeningeal growth, diagnosis of
DLGNT must be discussed. These cases usually demon-
strate 1p deletion or 1p/19q codeletion (but no IDH gene
mutation) in addition to KIAA1549-BRAF fusion and
synaptophysin expression [3]. In supratentorial compart-
ment, dysembryoplastic neuroepithelial tumors or gang-
liogliomas represent the most frequent differential
diagnoses. Dysembryoplastic neuroepithelial tumors usually
exhibit FGFR1 alteration (point mutations and internal
tandem duplication) and lack of KIAA1549-BRAF fusion
whereas gangliogliomas demonstrate frequent BRAFV600E
mutation in addition to CD34 expression [8, 9]. However,
KIAA1549-BRAF fusion has also been recorded in gang-
liogliomas as well as alteration in the FGFR1 gene can be
observed in pilocytic astrocytomas. Finally, in small biop-
sies, when Rosenthal fibers are lacking, and if an infiltrative
pattern is observed, differential diagnosis with diffuse
glioma might be questionable especially in cases occurring
in the midline. In these cases, when H3K27 histone muta-
tion is lacking, evidence for KIAA1549-BRAF fusion is of
utmost importance to assess pilocytic astrocytoma diag-
nosis. In our study, KIAA1549-BRAF fusion was recorded
in 20/40 pilocytic astrocytomas (50%), 3/18 gangliogliomas
(16.7%), and in 4/27 (14.8%) of neuroepithelial tumors that
remained difficult to classify (one pilocytic astrocytoma
versus ganglioglioma and three pilocytic astrocytomas
versus diffuse gliomas), but in none of the dysembryoplastic
neuroepithelial tumors. Whether true gangliogliomas dis-
play KIAA1549-BRAF fusion or whether these tumors
represent misclassified pilocytic astrocytomas is still a
matter of debate. Nevertheless, because KIAA1549-BRAF
fusion constitutively activates the MAP kinase pathway,
this alteration represents a target for drugs such as MEK
inhibitors, and therefore, the detection of this genetic
abnormality is of utmost importance in these tumors in the
context of clinical trials. Indeed, searching for KIAA1549-
BRAF fusion will be done in all samples from patients that Ta
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will be included in the incoming SIOP-LOGGIC phase III
clinical trial. In the context of KIAA1549-BRAF fusion
gene, the most reliable KIAA1549 exon to target to detect
KIAA1549-BRAF fusion was exon 4. Importantly, we also
showed that appropriate combinations of primers might be
used to define which exon (15 or 16) of the KIAA1549 gene
is involved in the KIAA1549-BRAF fusion. However, the
correlation with RNAseq results was not 100% and in
routine practice it is not currently necessary to decipher the
different combinations of KIAA1549-BRAF fusion tran-
scripts. We also learnt from our study that the highest mean
copy number variation value of the ratio between two exons
analyzed was never above 3, as expected for a duplication
involving one allele in almost all cells.
To conclude, the present study showed the usefulness of
DDPCR™ to assess KIAA1549-BRAF fusion from DNA
extracted from formalin-fixed paraffin-embedded tissue.
Evidence for BRAF duplication is both necessary and suf-
ficient to predict KIAA1549-BRAF fusion.
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